Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Post by barmac6on Jan 06, 2011 10:33am

432 Views

Post# 17932507

MD

The first thing I’m going to buy with my new found wealth is some underwear. I’ve ruined 3 pairs already today.

Depth by Price for T : HEM as of 2011-01-06 10:34:41

	Bid					Ask
price #shares ##orders	1.25 5,000 1	1.27 13,800 1	1.28 500 1	1.30 600 1	1.31 600 2	1.37 5,100 3	1.40 2,220 2	1.43 500 1	1.48 2,000 1	1.49 500 1